Modulation of P2X4/P2X7/Pannexin-1 sensitivity to extracellular ATP via Ivermectin induces a non-apoptotic and inflammatory form of cancer cell death (2015)

Peer-Reviewed Study · Draganov D, Gopalakrishna-Pillai S, Chen YR, Zuckerman N, Moeller S, Wang C, Ann D, Lee PP · November 10, 2015

Draganov D et al., 2015-11-10: Cell study showing ivermectin opens P2X4/P2X7-gated Pannexin-1 channels in breast cancer cells, producing a mixed apoptotic/necrotic, inflammatory (pyroptotic) cell death with ATP and HMGB1 release.

Using an FDA-approved anti-parasitic agent Ivermectin as a prototype agent to allosterically modulate P2X4 receptors, we can switch the balance between the dual pro-survival and cytotoxic functions of purinergic signaling in breast cancer cells.

Draganov D et al., 2015-11-10: Cell study showing ivermectin opens P2X4/P2X7-gated Pannexin-1 channels in breast cancer cells, producing a mixed apoptotic/necrotic, inflammatory (pyroptotic) cell death with ATP and HMGB1 release. C3 immunogenic cell death mechanism. Study type: cell lines in vitro (mouse and human triple-negative breast cancer cells); no animals in this paper. Country: USA (City of Hope, Duarte, CA). Concentrations: IC50 as low as 2 uM with extended exposure; 8 uM and above used for mechanistic experiments. Funder: US Department of Defense Breast Cancer Research Program awards W81XWH-11-1-0548 and W81XWH-12-1-0366 (to P.P.L.); NCI P30CA33572 core support. Declared conflicts: none stated. Product: ivermectin (Sigma/lab grade source in methods). Comparator: untreated cells and pathway inhibitors (KN-62, BAPTA-AM, CCCP). The paper describes the death mode as 'consistent with pyroptosis', not classical apoptosis. Study type: lab.